322 results on '"Catane R"'
Search Results
2. A Single Nucleotide Polymorphism in the RAD51 Gene Modifies Cancer Risk in BRCA2 but Not BRCA1 Carriers
3. Involvement of Heparanase and Extracellular Matrix-Bound Fibroblast Growth Factor in Tumor Progression
4. Modulation of Neovascularization and Metastasis by Species of Heparin
5. European Society for Medical Oncology (ESMO) Program for the Integration of Oncology and Palliative Care: a 5-year review of the Designated Centers’ incentive program
6. A new generation of Doxorubicin-loaded liposomes with improved localization in tumors: preclinical and clinical studies
7. Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin
8. How can medical oncologists deal with the new wave of genetic information about their patients?
9. Magnetic resonance guided focused ultrasound surgery. Ablation of soft tissue at bone–muscle interface in a porcine model
10. MR-guided focused ultrasound surgery (MRgFUS) for the palliation of pain in patients with bone metastases—preliminary clinical experience
11. Problems of opioid availability and accessibility across Europe: ESMO tackles the regulatory causes of intolerable and needless suffering
12. Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer
13. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer
14. ESMO takes a stand on supportive and palliative care
15. Prolonged testosterone suppression in prostate cancer with an implant releasing the GnRH agonist histrelin
16. Selected Anticancer Drugs in Phase I Trials in the United States (1979–1980)
17. The Rediscovery of DON (6-Diazo-5-oxo-L-norleucine)
18. A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA 1 carriers
19. The RAD51-135C SNP modifies breast and ovarian cancer risk in BRCA2 carriers, but not in BRCA1 carriers
20. Selected Anticancer Drugs in Phase I Trials in the United States (1979–1980)
21. Platinum Complexes in Cancer Chemotherapy
22. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families
23. Pain Palliation of Bone Metastases Using Magnetic Resonance Guided Focused Ultrasound - Multi-Center Multi-trial Results
24. Conclusions and Perspectives
25. MicroRNAs as prognostic markers for survival in renal cell carcinoma conventional type T 2-4.
26. Adoptive transfer of short-term cultured tumor-infiltrating lymphocytes (young TIL) in metastatic melanoma patients.
27. Identification of BRCA1/BRCA2 carriers by screening in the healthy population and its implications.
28. Does Concurrent Chemoradiotherapy Compromise the Delivery of Subsequent Sequential Gemcitabine in Locally Advanced Pancreatic Cancer?
29. MR Guided Focused Ultrasound Thermal Ablation: Clinical Applications and Potential
30. Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin
31. Metabolic syndrome, diabetes mellitus, and the subsequent development of prostate cancer
32. Superior pathological complete response to neo-adjuvant chemotherapy in breast cancer amongst women with BRCA1/2 mutations.
33. VIIIA.2 Pain management in elderly cancer patients
34. A phase I study of TPI 287, a third generation taxane, administered every 21 days in patients with advanced cancer
35. Stage at breast cancer diagnosis is more advanced in BRCA1 carriers but not in BRCA2 carriers
36. 2133
37. Postoperative chemoradiation for resected gastric cancer—The tolerability of the Macdonald regimen in the routine clinical practice setting in Israel
38. Breast cancer with HER2/neu over-expression and hormone receptor positive status: A distinct biology and natural history
39. Dose-dense neoadjuvant chemotherapy in breast cancer
40. Ghrelin, adiponectin and leptin in cancer cachexia
41. Dying Well—a guide to enabling a good death, 2nd edition
42. Melanoma risk in women with previous breast cancer
43. Consequences of death on group process during a long-term moderated Web-based support group
44. The Israeli experience with gefitinib (ZD1839) as single agent treatment of advanced non-small-cell lung cancer -a 3 years report
45. Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial
46. A designer inhibitor of a novel protein-kinase causes regression of human hormone refractory prostate cancer xenografts in nude mice
47. Synergistic antitumoral effect of the immunomodulator AS101 + paclitaxel (Taxol)
48. Breast & ovarian cancer risk in BRCA mutation carriers: Implications for prevention
49. Predominance of TH1 Response in Tumor-Bearing Mice and Cancer Patients Treated With AS 101
50. Bone marrow-sparing and prevention of alopecia by AS101 in non-small-cell lung cancer patients treated with carboplatin and etoposide.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.